Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06865339 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

Study acronym: TRIPL
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Nitin Ohri to Montefiore Medical Centerv7
  2. Lead sponsor: Albert Einstein College of Medicine to Nitin Ohriv6 Show 4 more changesShow less
    • Primary and study completion dates: Jul 2027 to Aug 2027
    • Start date changed from estimate of Jul 2025 to Aug 7, 2025
    • Collaborators: 1 to 4
    • Publications: 2 to 40
  3. Primary and study completion dates: Jun 2027 to Jul 2027
    • Start date: Jun 2025 to Jul 2025
    v5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: May 2027 to Jun 2027
    • Start date: May 2025 to Jun 2025
    • Site details revised
    v4
  5. Start date: Apr 2025 to May 2025v3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).
Trial Details
NCT Number NCT06865339
Lead Sponsor Montefiore Medical Center
Collaborators: Regeneron Pharmaceuticals, Henry Ford Health System, NYU Langone Health, University of Michigan
Conditions
(from sponsor)		 NSCLC, Locally Advanced
Enrollment 76 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov